Antibodies specific to the peptide were found in the blood of mice injected with ImMucin. Moreover, CD8+ T cells generated in mice vaccinated with ImMucin specifically recognized and eliminate murine breast cancer tumor cells transfected with the human MUC1 gene. Results with ImMucin were superior to  those of other MUC1 peptides including the 25mer BLP25 currently in phase III trial. These results serve as additional indications for the effectiveness of the company's approach.

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel. 

The ImMucin anti-MUC1 cancer vaccine has received regulatory approval to start a Phase I/II clinical study in Multiple Myeloma patients. The study is due to start in 2010 and will be carried in the Hadassah Medical center, Jerusalem.
ImMucin is a new class of immune-therapeutics to treat cancer. It is a therapeutic cancer vaccine which enhances the body’s immune response system to treat cancer.

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. A second product, mTbuVax™ for the treatment of Tuberculosis is currently in pre-clinical development. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel. 

Dr. Carmon will be presenting Vaxil's VaxHit™ pioneering technology for the identification of novel therapeutic vaccines.

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil is also developing a new vaccine for the treatment of tuberculosis, mTBuVax which is in pre-clinical studies. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.  

Approval has been obtained from the Assuta's hospital institutional review board (IRB), to test the vaccine on blood samples drawn from patients infected with Mtb. Mtb is one of the most ubiquitous pathogens in the world. It is estimated that roughly one third of the world's population is infected, resulting in 3 million deaths annually. It is an increasing problem in the developed as well as the developing world and there is a significant market opportunity due to the relative poor efficacy of the current vaccine, the BCG. This is an important milestone in the development of Vaxil's improved vaccine, which seeks to replace the BCG vaccine early in life as a prophylactic i.e before any exposure to Mtb bacteria and/or to increase anti-Mtb immune responses later in life when immunity to BCG-vaccinated individuals is reduced. Earlier this year, Vaxil announced that it was awarded a grant from the Israeli Office of the Chief Scientist to develop TbuVax.

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.  

Tuberculosis is a growing problem not just in the third world but also in western countries. Incidence rates in the developed world are rising rapidly due to the development of drug resistant strains of the disease, the ineffectiveness of current vaccines, global travel and the rise of TB as a co-factor with HIV infection. The global market for TB vaccines is estimated at around $1bn a year.

About Vaxil
Vaxil BioTherapeutics is a pioneer in the development of novel T cell synthetic vaccines for both therapeutic and prophylactic use. Using a proprietary technology VaxHit™ it has identified a large number of vaccine candidates in the fields of cancer and infectious diseases. The company’s lead product – ImMucin™, an anti-MUC1 therapeutic cancer vaccine has received regulatory permission to start Phase I/II clinical trials in Multiple Myeloma patients. Vaxil was established in 2007 by an experienced management team backed up by leading figures in the academic world. The company is based in Nes-Ziona, Israel.